2020-09-25

NeoDynamics is approaching launch of new pulse biopsy system NeoNavia - reputed international gynecologists and radiologists gained positive hands-on experience

NeoDynamics AB (publ), (Spotlight Stock Market: NEOD), today announced that the company is ready to launch the new pulse biopsy system NeoNavia. The biopsy system has been very well received at recent international Senology congresses in Vienna and Lucerne, and for the first-time physicians have gained hands-on experience of the final product.

NeoDynamics has recently participated in two scientific congresses where leading international experts in Senology discussed advancements within diagnosis and treatment of breast cancer; The Annual Congress of the Austrian Society of Senology, in Vienna, Austria, and the Annual Congress of the Swiss Society of Senology, in Lucerne, Switzerland. The congresses were the first Senology meetings following the pandemic that took place in real life, which enabled physicians to gain hands-on experience of the new biopsy system.

In conjunction with the joint congress of MIBB (Swiss working group for minimally invasive breast interventions) and the Swiss Society of Senology, the new biopsy system was presented by Dr Stefan Paepke, Klinikum rechts der Isar, from Munich, Germany. In addition, a specific certification course for breast vacuum biopsies was arranged by MIBB, which included a hands-on workshop, where physicians were able to test the final commercial version of NeoNavia for the first time.

“NeoNavia is certainly an exciting new biopsy technology and a useful new tool for breast cancer diagnosis. There was a high interest by the attendees to try the system both at the booth and in the hands-on workshop. I’m looking forward to using the platform in clinical practice and am delighted to join the NeoDynamics Advisory Board and help move this project forward “, said Dr. Claudia Kurtz, senior radiologist at Cantonal Hospital Lucerne and president of the MIBB working group.

“It was really exciting to see how the hands-on experience during the workshop increased the physicians understanding of the value that the new pulse biopsy technology brings, and how the three different needle options enable physicians to tailor the biopsy to the location and type of lesion”, said Kai-Uwe Schässburger, Ph.D. Director Clinical Development & Medical Affairs, NeoDynamics. “The value of hands-on experience cannot be underestimated and will become an integral part of our strategy when we introduce NeoNavia to a broader audience”.

The information was submitted for publication through the agency of the contact person set out below, at 08:45 CET on September 25, 2020.

For further information about NeoDynamics, please contact:                       

Anna Eriksrud, CEO NeoDynamics AB (publ), telephone: +46 708 444 966 , e-mail: anna.eriksrud@neodynamics.se, or

Jörgen Vrenning, CFO/IR NeoDynamics AB (publ), Telephone: +46 708 519 648, email: jorgen.vrenning@neodynamics.se

About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has an innovative biopsy system, NeoNavia®. The precision biopsy system is built on a patented micro-pulse technology, based on research at the Karolinska Institutet in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia® is evaluated at leading clinics in UK, Germany and Sweden. A commercial launch is expected in 2020.

About NeoNavia

NeoNavia is the brand name for the entire biopsy system intended to be used under ultrasound guidance. NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the micro-pulses enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

About the micro-pulse technology

The patented micro-pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, independent of tissue type. The pneumatic driver that generates micro-pulses is placed in a handheld instrument. With power from the base-unit, the driver accelerates the needle with great control even over a short distance, enabling its distinct stepwise insertion without the risk of destroying surrounding tissue. This facilitates ease of access and flexibility in sampling, even in very small lesions in delicate and difficult locations.